

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**  
**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

**VOLUNTARY ANNOUNCEMENT**  
**APPROVAL BY THE U.S. FDA FOR CLINICAL TRIAL OF**  
**THE MRNA HERPES ZOSTER VACCINE**  
**ITS HUMORAL AND CELLULAR IMMUNITY**  
**WAS SIGNIFICANTLY HIGHER THAN THOSE OF**  
**INTERNATIONALLY COMMERCIALY AVAILABLE**  
**RECOMBINANT SUBUNIT VACCINES**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The clinical trial approval for the mRNA herpes zoster vaccine has been recently received from the U.S. Food and Drug Administration (“**FDA**”). This is the second innovative vaccine product of the Group approved by the U.S. FDA for clinical trials, following the mRNA RSV vaccine, which marks a new milestone in the Group’s globalization strategy.

In preclinical testing, results from a third-party testing unit showed that the Group’s mRNA herpes zoster vaccine specific T-cell immunity, specific IgG antibody titers, and fluorescent antibody to membrane antigen (FAMA) titers were significantly higher than those of international commercially available recombinant subunit control vaccines.

Herpes zoster is an infectious dermatosis caused by reactivation of the varicella-zoster virus (VZV), which has been latent in the body for a long time. The general population is universally susceptible to VZV, and serological evidence indicates that the infection rate of VZV among adults exceeds 90%. The incidence rate of herpes zoster is 3‰ to 5‰ person/year, and 3‰ to 10‰ person/year in the Asia-Pacific region, with an annual increase of 2.5% to 5.0%. Risk factors for VZV reactivation include: advanced age, trauma, systemic diseases (such as diabetes, kidney disease, fever, hypertension, etc.), human immunodeficiency virus (HIV) infection, immunosuppression caused by malignant tumors, etc. For people aged 50 or above, VZV-specific cellular immune function gradually decreases with age. As a result, the incidence, hospitalization rate and case fatality rate of herpes zoster gradually increase. Vaccination against herpes zoster is an effective measure to inhibit the onset of herpes zoster. The herpes zoster vaccine is vaccinated to prevent herpes zoster, postherpetic neuralgia (PHN) and other complications by inhibiting VZV reactivation. [The information is sourced from the Chinese Expert Consensus on the Diagnosis and Treatment of Herpes Zoster (2022 Edition)]

Currently, no mRNA herpes zoster vaccine has been approved for marketing in the world. The vaccination rate of herpes zoster vaccine in the target population is only about 0.1%, leaving much room for improvement. In 2024, the global sales of GSK herpes zoster vaccine reached approximately US\$4.310 billion. According to the forecast of China Insights Industry Consultancy Limited, an industry consultant, it is expected that the market size of herpes zoster vaccines in China will reach approximately RMB20.0 billion and the global market size will reach approximately US\$23.9 billion by 2030. Upon approval of the product for marketing, it will bring considerable growth to the Group's performance. The mRNA herpes zoster vaccine of AIM is expected to reshape the market landscape due to its advantages in terms of safety and immunogenicity.

The Group is one of the enterprises that takes the lead in developing mRNA vaccine products in China, and also one of the first batch of domestic vaccine enterprises that has obtained an independent patent for mRNA technology. The Group has a mature mRNA vaccine research and development system. Meanwhile, the Group has established a sound quality management system for mRNA vaccines and a commercial-scale production workshop in line with GMP standards. The mRNA technology platform has been verified by tens of thousands of human clinical trials data of mRNA vaccine products. The Group has now smoothed the whole life

cycle process such as the research, development and production of mRNA vaccines, allowing for rapid achievement of the industrialization of mRNA vaccine products after obtaining clinical approval and accelerating the commercialization process of vaccine products. As a new blockbuster product in the global vaccine market, this product is expected to become a new growth driver for the Group after its marketing.

By order of the Board  
**AIM Vaccine Co., Ltd.**  
**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, March 23, 2025

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.*